CD274 and anemia: This study allowed for extensive univariate analysis for OS, PFS, and clinical benefit, with applications to the use of immunotherapy combinations in clinical practice (e.g., negative impact on prognosis for older age, PS = 2, stage IVB, anemia, NLR > 3.81, use of corticoids early in the treatment; blunting of prognostic differences related to histology and PD-L1 expression level; usefulness of immunotherapy even in patients with a reserved prognosis with brain or liver metastases).